The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Clinical Impact of the Cell-of-Origin Classification and the MYC / BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group
Abstract
Purpose: To explore the prognostic impact and interdependence of the cell-of-origin (COO) classification, dual expression (DE) of MYC and BCL2 proteins, and MYC, BCL2, and BCL6 translocations in two prospectively randomized clinical trials of patients with diffuse large B-cell lymphoma (DLBCL). Patients and Methods: Overall, 452 formalin-fixed paraffin-embedded samples from two prospective, randomized DLBCL trials (RICOVER-60, prospective, randomized study for patients > 60 years, all IPI groups; and R-MegaCHOEP, prospective, randomized study for patients ≤ 60 years with age-adjusted IPI 2,3) of the German High-Grade Non-Hodgkin Lymphoma Study Group were analyzed with the Lymph2Cx assay for COO classification, with immunohistochemistry for MYC and BCL2, and with fluorescent in situ hybridization for MYC, BCL2, and BCL6 rearrangements. Results: COO classification was successful in 414 of 452 samples. No significant differences with respect to COO (activated B-cell [ABC]–like DLBCL v germinal center B-cell [GCB]–like DLBCL) were observed in event-free survival, progression-free survival, and overall survival in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in the RICOVER-60 trial. Also, no differences with respect to COO were observed in multivariable analyses adjusted for International Prognostic Index factors in event-free survival (hazard ratio [HR] of ABC-like disease v GCB-like disease, 1.0; 95% CI, 0.6 to 1.6; P = .93), progression-free survival (HR, 1.1; 95% CI, 0.6 to 1.8; P = .82), and overall survival (HR, 1.0; 95% CI, 0.6 to 1.8; P = .96). Similar results were observed in the R-MegaCHOEP trial. In patients treated with R-CHOP, DE status was associated with significantly inferior survival compared with nonDE within the GCB, but not within the ABC subgroup. DE status was associated with significantly inferior outcome compared with patients with ABC-like DLBCL without DE (5-year PFS rate, 39% [95% CI,19% to 59%] v 68% [95% CI, 52% to 85%]; P = .03) and compared with patients with GCB-like DLBCL without DE. When data from patients with nonDE were analyzed separately, the outcome of patients in the ABC subgroup was inferior to that of patients in the GCB subgroup (5-year PFS rate, 68% [95% CI, 52% to 85%] v 85% [95% CI, 74% to 96%]; P = .04). Conclusion: COO profiling in two prospective randomized DLBCL trials failed to identify prognostic subgroups, whereas dual expression of MYC and BCL2 was predictive of poor survival. Evaluation of prognostic or predictive biomarkers in the management of DLBCL, such as the COO, within prospective clinical trials will be important in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., et al. (2016) · Blood · doi:10.1182/blood-2016-01-643569 · Cited by 7,831
Self-citationDirect multiplexed measurement of gene expression with color-coded probe pairs
Geiss, G. K., Bumgarner, R. E., Birditt, B., Dahl, T., Dowidar, N., Dunaway, D. L., Fell, H. P., Ferree, S., George, R. D., Grogan, T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1385 · Cited by 2,066
Wilson, W. H., O'Connor, O. A., Czuczman, M. S., LaCasce, A. S., Gerecitano, J. F., Leonard, J. P., Tulpule, A., Dunleavy, K., Xiong, H., Chiu, Y.-L., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70261-8 · Cited by 876
Cited by
Campo, E., Jaffe, E. S., Cook, J. R., Quintanilla-Martinez, L., Swerdlow, S. H., Anderson, K. C., Brousset, P., Cerroni, L., de Leval, L., Dirnhofer, S., et al. (2022) · Blood · doi:10.1182/blood.2022015851 · Cited by 1,608
Self-citationDiffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment
Liu, Y., & Barta, S. K. (2019) · American Journal of Hematology · doi:10.1002/ajh.25460 · Cited by 488
Sha, C., Barrans, S., Cucco, F., Bentley, M. A., Care, M. A., Cummin, T., Kennedy, H., Thompson, J. S., Uddin, R., Worrillow, L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01314 · Cited by 300
Carpio, C., Bouabdallah, R., Ysebaert, L., Sancho, J.-M., Salles, G., Cordoba, R., Pinto, A., Gharibo, M., Rasco, D., Panizo, C., et al. (2020) · Blood · doi:10.1182/blood.2019002395 · Cited by 72
The impact of SOCS1 mutations in diffuse large B‐cell lymphoma
Mellert, K., Martin, M., Lennerz, J. K., Lüdeke, M., Staiger, A. M., Kreuz, M., Löffler, M., Schmitz, N., Trümper, L., Feller, A. C., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16147 · Cited by 17
Self-citation
Metadata
- Authors
- Staiger, A. M., Ziepert, M., Horn, H., Scott, D. W., Barth, T. F. E., Bernd, H.-W., Feller, A. C., Klapper, W., Szczepanowski, M., Hummel, M., Stein, H., Lenze, D., Hansmann, M.-L., Hartmann, S., Möller, P., Cogliatti, S., Lenz, G., Trümper, L., Löffler, M., Schmitz, N., Pfreundschuh, M., Rosenwald, A., Ott, G., & for the German High-Grade Lymphoma Study Group
- Venue
- Journal of Clinical Oncology
- Published
- 2017-08-01
- Volume
- 35
- Issue
- 22
- Pages
- 2515-2526
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2614435853
- Cited by
- 221
- References
- 3
- FWCI
- 19.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Impact of the Cell-of-Origin Classification and the MYC / BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. https://app.cochat.ai/papers/10.1200/jco.2016.70.3660
- The paper
- Staiger, A. M., Ziepert, M., Horn, H., Scott, D. W., Barth, T. F. E., Bernd, H.-W., Feller, A. C., Klapper, W., Szczepanowski, M., Hummel, M., Stein, H., Lenze, D., Hansmann, M.-L., Hartmann, S., Möller, P., Cogliatti, S., Lenz, G., Trümper, L., Löffler, M., . . . for the German High-Grade Lymphoma Study Group. (2017). Clinical Impact of the Cell-of-Origin Classification and the MYC / BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.70.3660
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.